Farhadfar, N., Strickland, S., Bajel, A., Eghtedar, A., Garrison, B., Emery, R., Rajangam, K., Schiller, G., Ravandi, F. (2025). Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood. https://doi.org/10.1182/blood-2025-1044